My Take on New Ocular Screening Guidelines for Plaquenil
A recent article published by the American Academy of Ophthalmology (AAO) presented new recommendations for screening of patients being managed with hydroxychloroquine (HCQ).
Effective Interferon-Free Regimen for HCV-Cryoglobulinemic Vasculitis
Rheumatologists have been challenged to treat hepatitis C virus (HCV)-induced rheumatic disease since discovery of the virus in 1989.
My Take on New Ocular Screening Guidelines for Plaquenil
A recent article published by the American Academy of Ophthalmology (AAO) presented new recommendations for screening of patients being managed with hydroxychloroquine (HCQ).
The Arthritis Spectrum after Lyme Infection - Something New
Symptoms attributed to chronic Lyme disease are the bane of a rheumatologist’s existence. We often see patients referred for a variety of nonspecific complaints that do not resolve after antibiotic therapy, including the so-called post-Lyme disease syndrome.
RheumNow Week in Review – 30 September 2016
Dr. Jack Cush Reviews highlights in the news and journals from the past week on RheumNow.com:
Ilaris Gets FDA Approval for Rare Febrile Disorders
The U.S. Food and Drug Administration has approved three new indications for canakinumab (Ilaris). The drug was previously approved for use in systemic JIA (age 2 yrs and older) and CAPS (cryopyrin-associated periodic syndromes).
The RheumNow Week in Review – 9 September 2016
Dr. Jack Cush reviews highlight in news and journal reports from this week on RheumNow.com
RheumNow Week in Review – 19 August 2016
Dr. Cush reviews the RheumNow.com highlights in rheumatology for the week ending 19 August 2016:
Rheumatologists May be Unaware of New Hydroxychloroquine Retinopathy Monitoring Guidelines
Rheumatologists are well-acquainted with the rules for hydroxychloroquine (HCQ) retinopathy screening: A) annual visits to the ophthalmologist and B) maintain HCQ doses at less than 6.5 mg/kg to avoid retinopathy.
Serious Infections are Not Increased in HIV Patients Treated with TNF Inhibitors
Infections are a concern for many when using tumor necrosis factor-α inhibitor (TNFi) therapy to treat inflammatory disorders. Even moreso in those at higher risk.
RheumNow Week in Review - 29 July 2016
Dr Jack Cush reviews this week's highlights from RheumNow.com.
Novel Rise of Combined Dermatology-Rheumatology Clinics
Rheumatology News has a novel online report about combined rheumatology-dermatology clinics. In the last several years, there have been a few of these in operation (Boston, Chicago, Rhode Island).
